{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:39:53Z","timestamp":1794447593594,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis (Ps) is a chronic inflammatory skin disease with systemic manifestations, such as psoriatic arthritis (PsA), cardiovascular and psychiatric complications, and subsequent negative effects on patients\u2019 quality of life. Although biologics targeting specific disease mediators have become a mainstay in Ps treatment, exploration of new disease targets to improve treatment is still needed. Here we show that fatty-acid binding protein 5 (Fabp5) promotes skin inflammation through a therapeutically relevant modulation of the ferroptotic response. In epidermal-specific inducible c-Jun and JunB knockout (DKO*) mice, a preclinical model for Ps with PsA-like manifestations, dermal fat is reduced, serum free fatty acids (FFA) decreased, and \u03b2-hydroxybutyric acids (\u03b2-OHB) altered. Comparing RNA-seq and proteomic datasets from DKO* mice and Ps patients revealed shared alterations in fatty acid metabolism and ferroptosis signatures. Specifically, increased expression of Fabp5 and decreased expression of glutathione peroxidase 4 (Gpx4), a lipid-modifying enzyme and ferroptosis suppressor, are observed in the epidermis of DKO* mice and Ps patients. Treatment of DKO* mice with the Fabp inhibitor BMS increased Gpx4 expression, reduced lipid peroxidation products and neutrophil infiltration, ameliorated the skin phenotype, and alleviated keratinocyte hyperproliferation without affecting systemic IL-17a signaling and PsA-like manifestations. Importantly, dysregulated epidermal Fabp5 and Gpx4 expression was normalized after anti-IL17a or anti-TNF\u03b1 antibody administration in DKO* mice, as well as in Ps patients treated with the corresponding Ps biologics. Furthermore, treatment with the ferroptosis inhibitor, liproxstatin-1, suppressed Ps-like skin thickening in DKO* mice, but did not affect the joint phenotype. These results support a functional and disease-relevant link between Fabp5, Gpx4 and ferroptosis in the skin that should be therapeutically exploited.<\/jats:p>","DOI":"10.1038\/s41418-025-01630-4","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T15:38:12Z","timestamp":1765035492000},"page":"1333-1344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Fatty acid-binding protein 5 aggravates psoriasis and psoriasis-like disease through ferroptosis"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-5861","authenticated-orcid":false,"given":"Kamil","family":"Mieczkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-2420","authenticated-orcid":false,"given":"Latifa","family":"Bakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna S.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-0196","authenticated-orcid":false,"given":"Erwin F.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"1630_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2340\/actadv.v105.42945","volume":"105","author":"C Skayem","year":"2025","unstructured":"Skayem C, Taieb C, Halioua B, Baissac C, Saint AM. Epidemiology of Psoriasis: a worldwide global study. Acta Derm Venereol. 2025;105:2\u20134.","journal-title":"Acta Derm Venereol"},{"key":"1630_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133:377\u201385.","journal-title":"J Investig Dermatol"},{"key":"1630_CR3","doi-asserted-by":"crossref","unstructured":"Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:1\u201317.","DOI":"10.1038\/nrdp.2016.82"},{"key":"1630_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jdv.15159","volume":"33","author":"Fern\u00e1ndez-AJM","year":"2019","unstructured":"Fern\u00e1ndez-AJM, Arbon\u00e9s G, Buti-SM, Betriu BA, Sanmartin NV, Ortega BM, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. a population-based study. J Eur Acad Dermatol Venereol. 2019;33:128\u201335.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1630_CR5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/art.40499","volume":"70","author":"ME Husni","year":"2018","unstructured":"Husni ME, Schwartzman S, Podobnik J, Garg A, Gottlieb AB. Correlation of high-density lipoprotein\u2013associated paraoxonase 1 activity with systemic inflammation, disease activity, and cardiovascular risk factors in psoriatic disease. Arthritis Rheumatol. 2018;70:1240\u201350.","journal-title":"Arthritis Rheumatol"},{"key":"1630_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jaad.2013.08.042","volume":"70","author":"C Ryan","year":"2014","unstructured":"Ryan C, Korman NJ, Gelfand JM, Lim HM, Elmets CA, Feldman SR, et al. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014;70:146\u201367.","journal-title":"J Am Acad Dermatol"},{"key":"1630_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3899\/jrheum.101124","volume":"38","author":"WH Boehncke","year":"2011","unstructured":"Boehncke WH, Gladman DD, Chandran V. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38:567\u201371.","journal-title":"J Rheumatol"},{"key":"1630_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","volume":"400","author":"N Conrad","year":"2022","unstructured":"Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022;400:733\u201343.","journal-title":"Lancet"},{"key":"1630_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","volume":"163","author":"K Abuabara","year":"2010","unstructured":"Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163:586\u2013592.","journal-title":"Br J Dermatol"},{"key":"1630_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1630_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1468-3083.2010.03600.x","volume":"24","author":"N Meyer","year":"2010","unstructured":"Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1630_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1630_CR13","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1016\/j.jid.2017.07.822","volume":"137","author":"I Snekvik","year":"2017","unstructured":"Snekvik I, Smith CH, Nilsen TIL, Langan SM, Modalsli EH, Romundstad PR, et al. Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT Study. J Investig Dermatol. 2017;137:2484\u201390.","journal-title":"J Investig Dermatol"},{"key":"1630_CR14","first-page":"5","volume":"10","author":"HA Alotaibi","year":"2018","unstructured":"Alotaibi HA. Effects of weight loss on psoriasis: a review of clinical trials. Cureus. 2018;10:5\u201311.","journal-title":"Cureus"},{"key":"1630_CR15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/bjd.12735","volume":"170","author":"L Naldi","year":"2014","unstructured":"Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A, et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol. 2014;170:634\u201342.","journal-title":"Br J Dermatol"},{"key":"1630_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","volume":"149","author":"P Jensen","year":"2013","unstructured":"Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149:795\u2013801.","journal-title":"JAMA Dermatol"},{"key":"1630_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20184347","volume":"20","author":"K Kamiya","year":"2019","unstructured":"Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20:1\u201314.","journal-title":"Int J Mol Sci"},{"key":"1630_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301\u201315.","journal-title":"Lancet"},{"key":"1630_CR19","doi-asserted-by":"crossref","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13:1\u201313.","DOI":"10.1038\/s41419-022-04523-3"},{"key":"1630_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.freeradbiomed.2009.06.033","volume":"47","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med. 2009;47:891\u2013905.","journal-title":"Free Radic Biol Med"},{"key":"1630_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10030367","volume":"10","author":"I Jarocka-Karpowicz","year":"2020","unstructured":"Jarocka-Karpowicz I, Biernacki M, Wro\u0144ski A, G\u0119gotek A, Skrzydlewska E. Cannabidiol effects on phospholipid metabolism in keratinocytes from patients with psoriasis vulgaris. Biomolecules. 2020;10:1\u201320.","journal-title":"Biomolecules"},{"key":"1630_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21207608","volume":"21","author":"P Karabowicz","year":"2020","unstructured":"Karabowicz P, Wro\u0144ski A, Ostrowska H, Waeg G, Zarkovic N, Skrzydlewska E. Reduced proteasome activity and enhanced autophagy in blood cells of psoriatic patients. Int J Mol Sci. 2020;21:1\u201315.","journal-title":"Int J Mol Sci"},{"key":"1630_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells7100159","volume":"7","author":"E Ambro\u017cewicz","year":"2018","unstructured":"Ambro\u017cewicz E, W\u00f3jcik P, Wro\u0144ski A, \u0141uczaj W, Jastrz\u0105b A, \u017barkovi\u0107 N, et al. Pathophysiological alterations of redox signaling and endocannabinoid system in granulocytes and plasma of psoriatic patients. Cells. 2018;7:1\u201318.","journal-title":"Cells"},{"key":"1630_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s12291-010-0043-9","volume":"25","author":"DP Kadam","year":"2010","unstructured":"Kadam DP, Suryakar AN, Ankush RD, Kadam CY, Deshpande KH. Role of oxidative stress in various stages of psoriasis. Indian J Clin Biochem. 2010;25:388\u201392.","journal-title":"Indian J Clin Biochem"},{"key":"1630_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.cell.2020.07.027","volume":"182","author":"B Li","year":"2020","unstructured":"Li B, Hao J, Zeng J, Sauter ER. SnapShot: FABP functions. Cell. 2020;182:1066.e1.","journal-title":"Cell"},{"key":"1630_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd2589","volume":"7","author":"M Furuhashi","year":"2008","unstructured":"Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489\u2013503.","journal-title":"Nat Rev Drug Discov"},{"key":"1630_CR27","doi-asserted-by":"publisher","first-page":"113449","DOI":"10.1016\/j.celrep.2023.113449","volume":"42","author":"J Hao","year":"2023","unstructured":"Hao J, Yu J, Yorek MS, Yu CL, Pope RM, Chimenti MS, et al. Keratinocyte FABP5-VCP complex mediates recruitment of neutrophils in psoriasis. Cell Rep. 2023;42:113449.","journal-title":"Cell Rep"},{"key":"1630_CR28","doi-asserted-by":"crossref","unstructured":"Peng H, Xin S, Pfeiffer S, M\u00fcller C, Merl PJ, Hauck SM, et al. Fatty acid-binding protein 5 is a functional biomarker and indicator of ferroptosis in cerebral hypoxia. Cell Death Dis. 2024;15:1\u201312.","DOI":"10.1038\/s41419-024-06681-y"},{"key":"1630_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04284-5","volume":"12","author":"Y Shou","year":"2021","unstructured":"Shou Y, Yang L, Yang Y, Xu J. Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. Cell Death Dis. 2021;12:1\u201310.","journal-title":"Cell Death Dis"},{"key":"1630_CR30","doi-asserted-by":"crossref","unstructured":"Vats K, Tian H, Singh K, Tyurina YY, Sparvero LJ, Tyurin VA, et al. Ferroptosis of select skin epithelial cells initiates and maintains chronic systemic immune-mediated psoriatic disease. J Clin Investig. 2024;135:1\u201316.","DOI":"10.1172\/JCI183219"},{"key":"1630_CR31","doi-asserted-by":"crossref","unstructured":"Romanowska M, Reilly L, Palmer CNA, Gustafsson MCU & Foerster J. Activation of PPAR\u03b2\/\u03b4 causes a psoriasis-like skin disease in vivo. PLoS ONE. 2010;5. e9701:1\u201314","DOI":"10.1371\/journal.pone.0009701"},{"key":"1630_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nm1162","volume":"11","author":"S Sano","year":"2005","unstructured":"Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med. 2005;11:43\u201349.","journal-title":"Nat Med"},{"key":"1630_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.immuni.2018.05.012","volume":"49","author":"M Wang","year":"2018","unstructured":"Wang M, Zhang S, Zheng G, Huang J, Songyang Z, Zhao X, et al. Gain-of-function mutation of card14 leads to spontaneous psoriasis-like skin inflammation through enhanced keratinocyte response to IL-17A. Immunity. 2018;49:66\u201379.e5.","journal-title":"Immunity"},{"key":"1630_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.56720","volume":"9","author":"J Manils","year":"2020","unstructured":"Manils J, Webb LV, Howes A, Janzen J, Boeing S, Bowcock AM, et al. Card14e138a signalling in keratinocytes induces TNF-dependent skin and systemic inflammation. Elife. 2020;9:1\u201332.","journal-title":"Elife"},{"key":"1630_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature03963","volume":"437","author":"R Zenz","year":"2005","unstructured":"Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437:369\u201375.","journal-title":"Nature"},{"key":"1630_CR36","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.jid.2018.03.1525","volume":"138","author":"M Mellett","year":"2018","unstructured":"Mellett M, Meier B, Mohanan D, Schairer R, Cheng P, Satoh TK, et al. CARD14 Gain-of-function mutation alone is sufficient to drive IL-23\/IL-17\u2013mediated psoriasiform skin inflammation in vivo. J Investig Dermatol. 2018;138:2010\u201323.","journal-title":"J Investig Dermatol"},{"key":"1630_CR37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41598-019-56343-9","volume":"10","author":"L Chen","year":"2020","unstructured":"Chen L, Deshpande M, Grisotto M, Smaldini P, Garcia R, He Z, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10:4\u201314.","journal-title":"Sci Rep"},{"key":"1630_CR38","first-page":"1","volume":"11","author":"LN Gago","year":"2019","unstructured":"Gago LN, Mellor LF, Meg\u00edas D, Mart\u00edn SG, Izeta A, Jimenez F, et al. Role of bulge epidermal stem cells and TSLP signaling in psoriasis. EMBO Mol Med. 2019;11:1\u201321.","journal-title":"EMBO Mol Med"},{"key":"1630_CR39","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2022-222229","volume":"81","author":"LF Mellor","year":"2022","unstructured":"Mellor LF, Gago LN, Bakiri L, Schmidt FN, Busse B, Rauber S, et al. Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. Ann Rheum Dis. 2022;81:1400\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1630_CR40","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.immuni.2013.11.011","volume":"39","author":"HB Schonthaler","year":"2013","unstructured":"Schonthaler HB, Guinea-Viniegra J, Wculek SK, Ruppen I, Xim\u00e9nez EP, Gu\u00edo CA, et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity. 2013;39:1171\u201381.","journal-title":"Immunity"},{"key":"1630_CR41","doi-asserted-by":"publisher","first-page":"21264","DOI":"10.1073\/pnas.0907550106","volume":"106","author":"HB Schonthaler","year":"2009","unstructured":"Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA. 2009;106:21264\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1630_CR42","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.15252\/emmm.201404114","volume":"6","author":"E Glitzner","year":"2014","unstructured":"Glitzner E, Korosec A, Brunner PM, Drobits B, Amberg N, Schonthaler HB, et al. Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol Med. 2014;6:1312\u201327.","journal-title":"EMBO Mol Med"},{"key":"1630_CR43","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1007\/s11033-021-06461-3","volume":"48","author":"D Koz\u0142owska","year":"2021","unstructured":"Koz\u0142owska D, My\u015bliwiec H, Harasim-Symbor E, Milewska AJ, Chabowski A, Flisiak I. Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis. Mol Biol Rep. 2021;48:4421\u20139.","journal-title":"Mol Biol Rep"},{"key":"1630_CR44","unstructured":"Berger WT, Ralph BP, Kaczocha M, Sun J, Balius TE, Rizzo RC, et al. Targeting fatty acid binding protein (FABP) anandamide transporters\u2014a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS ONE. 2012;7:e50968."},{"key":"1630_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0094200","volume":"9","author":"M Kaczocha","year":"2014","unstructured":"Kaczocha M, Rebecchi MJ,\u00a0Ralph BP,\u00a0Teng\u00a0 YG,\u00a0Berger WT, Galbavy W\u00a0et al. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS ONE. 2014;9:1\u201310.","journal-title":"PLoS ONE"},{"key":"1630_CR46","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.xjidi.2021.100094","volume":"2","author":"J Liu","year":"2022","unstructured":"Liu J, Chang HW, Grewal R, Cummins DD, Bui A, Beck KM, et al. Transcriptomic profiling of plaque psoriasis and cutaneous T-cell subsets during treatment with secukinumab. JID Innov. 2022;2:100094.","journal-title":"JID Innov"},{"key":"1630_CR47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1021\/acscentsci.7b00028","volume":"3","author":"O Zilka","year":"2017","unstructured":"Zilka O, Shah R, Li B, Friedmann Angeli JP, Griesser M, Conrad M, et al. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent Sci. 2017;3:232\u201343.","journal-title":"ACS Cent Sci"},{"key":"1630_CR48","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","volume":"111","author":"K Furue","year":"2018","unstructured":"Furue K, Ito T, Furue M. Differential efficacy of biologic treatments targeting the TNF-\u03b1\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine. 2018;111:182\u20138.","journal-title":"Cytokine"},{"key":"1630_CR49","doi-asserted-by":"crossref","unstructured":"Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19:1\u201327.","DOI":"10.3390\/ijms19020530"},{"key":"1630_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/PTT.S380486","volume":"12","author":"A Al-Janabi","year":"2022","unstructured":"Al-Janabi A, Yiu Z. Biologics in psoriasis: updated perspectives on long-term safety and risk management [corrigendum]. Psoriasis Targets Ther. 2022;12:187\u20138.","journal-title":"Psoriasis Targets Ther"},{"key":"1630_CR51","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.celrep.2021.109235","volume":"35","author":"C Xu","year":"2021","unstructured":"Xu C, Sun S, Johnson T, Qi R, Zhang S, Zhang J, et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35:109235.","journal-title":"Cell Rep"},{"key":"1630_CR52","doi-asserted-by":"crossref","unstructured":"Jin R, Hao J, Yu J, Wang P, Sauter ER, Li B. Role of FABP5 in T cell lipid metabolism and function in the tumor microenvironment. Cancers. 2023;15:1\u201315.","DOI":"10.3390\/cancers15030657"},{"key":"1630_CR53","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s42003-024-07180-8","volume":"7","author":"X Yang","year":"2024","unstructured":"Yang X, Liu Y, Wang Z, Jin Y, Gu W. Ferroptosis as a new tool for tumor suppression through lipid peroxidation. Commun Biol. 2024;7:1475.","journal-title":"Commun Biol"},{"key":"1630_CR54","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.molcel.2020.10.010","volume":"80","author":"N Takahashi","year":"2020","unstructured":"Takahashi N, Cho P, Selfors LM, Kuiken HJ, Kaul R, Fujiwara T, et al. 3D Culture models with CRISPR screens reveal hyperactive NRF2 as a prerequisite for spheroid formation via regulation of proliferation and ferroptosis. Mol Cell. 2020;80:828\u2013844.e6.","journal-title":"Mol Cell"},{"key":"1630_CR55","doi-asserted-by":"crossref","unstructured":"Jimenez R, Toral M, G\u00f3mez-Guzm\u00e1n M, Romero M, Sanchez M, Mahmoud AM, et al. The role of Nrf2 signaling in PPAR\u03b2\/\u03b4-mediated vascular protection against hyperglycemia-induced oxidative stress. Oxid Med Cell Longev. 2018;2018:1\u201312.","DOI":"10.1155\/2018\/5852706"},{"key":"1630_CR56","doi-asserted-by":"crossref","unstructured":"Mieczkowski K, Bakiri L, Griss J & Wagner EF. A sex-specific anti-inflammatory role for p62 in psoriasis-like disease. J Investig Dermatol. 2025;145:2763\u20132774.e11.","DOI":"10.1016\/j.jid.2025.04.004"},{"key":"1630_CR57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jdermsci.2012.09.002","volume":"68","author":"T Miyake","year":"2012","unstructured":"Miyake T, Ogawa E, Mikoshiba A, Kobayashi A, Hosoe H, Kashiwabara S, et al. Epidermal-type FABP is a predictive marker of clinical response to systemic treatment and ultraviolet therapy in psoriatic skin lesions. J Dermatol Sci. 2012;68:199\u2013202.","journal-title":"J Dermatol Sci"},{"key":"1630_CR58","doi-asserted-by":"publisher","first-page":"106318","DOI":"10.1016\/j.phrs.2022.106318","volume":"182","author":"B Yan","year":"2022","unstructured":"Yan B, Liu P, Yi X, Li J, Liu N, Zhu W, et al. Topical VX-509 attenuates psoriatic inflammation through the STAT3\/FABP5 pathway in keratinocytes. Pharmacol Res. 2022;182:106318.","journal-title":"Pharmacol Res"},{"key":"1630_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0415-3","volume":"9","author":"WR Swindell","year":"2017","unstructured":"Swindell WR, Michaels KA, Sutter AJ, Diaconu D, Fritz Y, Xing X, et al. Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis. Genome Med. 2017;9:1\u201321.","journal-title":"Genome Med"},{"key":"1630_CR60","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/exd.14479","volume":"31","author":"MP Vinardell","year":"2022","unstructured":"Vinardell MP. Methodological shortcomings in the reports of the imiquimod psoriatic model. Exp Dermatol. 2022;31:299\u2013303.","journal-title":"Exp Dermatol"},{"key":"1630_CR61","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/jid.2013.52","volume":"133","author":"A Sengupta","year":"2013","unstructured":"Sengupta A, Lichti UF, Carlson BA, Cataisson C, Ryscavage AO, Mikulec C, et al. Targeted disruption of glutathione peroxidase 4 in mouse skin epithelial cells impairs postnatal hair follicle morphogenesis that is partially rescued through inhibition of COX-2. J Investig Dermatol. 2013;133:1731\u201341.","journal-title":"J Investig Dermatol"},{"key":"1630_CR62","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrendo.2015.122","volume":"11","author":"GS Hotamisligil","year":"2015","unstructured":"Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs - Mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11:592\u2013605.","journal-title":"Nat Rev Endocrinol"},{"key":"1630_CR63","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.cdd.4401713","volume":"13","author":"DJ Kim","year":"2006","unstructured":"Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPAR\u03b2\/\u03b4 selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 2006;13:53\u201360.","journal-title":"Cell Death Differ"},{"key":"1630_CR64","doi-asserted-by":"crossref","unstructured":"Blunder S, Pavel P, Minzaghi D, Dubrac S. PPARdelta in affected atopic dermatitis and psoriasis: a possible role in metabolic reprogramming. Int J Mol Sci 2021;22:1\u201319.","DOI":"10.3390\/ijms22147354"},{"key":"1630_CR65","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1046\/j.1523-1747.1998.00439.x","volume":"111","author":"M Rivier","year":"1998","unstructured":"Rivier M, Safonova I, Lebrun P, Griffiths CE, Ailhaud G, Michel S. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Investig Dermatol. 1998;111:1116\u201321.","journal-title":"J Investig Dermatol"},{"key":"1630_CR66","first-page":"854","volume":"96","author":"JC Chamcheu","year":"2016","unstructured":"Chamcheu JC, Chaves-Rodriquez MI, Adhami VM, Siddiqui IA, Wood GS, Longley BJ, et al. Upregulation of PI3K\/AKT\/mTOR, FABP5 and PPAR\u03b2\/\u03b4 in human psoriasis and imiquimod-induced murine psoriasiform dermatitis model. Acta Derm Venereol. 2016;96:854\u20136.","journal-title":"Acta Derm Venereol"},{"key":"1630_CR67","doi-asserted-by":"publisher","first-page":"102547","DOI":"10.1016\/j.redox.2022.102547","volume":"59","author":"Q Guo","year":"2023","unstructured":"Guo Q, Kawahata I, Cheng A, Wang H, Jia W, Yoshino H, et al. Fatty acid-binding proteins 3 and 5 are involved in the initiation of mitochondrial damage in ischemic neurons. Redox Biol. 2023;59:102547.","journal-title":"Redox Biol"},{"key":"1630_CR68","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jid.2018.02.003","volume":"138","author":"AV Sorokin","year":"2018","unstructured":"Sorokin AV, Domenichiello AF, Dey AK, Yuan ZX, Goyal A, Rose SM, et al. Bioactive lipid mediator profiles in human psoriasis skin and blood. J Investig Dermatol. 2018;138:1518\u201328.","journal-title":"J Investig Dermatol"},{"key":"1630_CR69","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1073\/pnas.72.12.5130","volume":"72","author":"S Hammarstr\u00f6m","year":"1975","unstructured":"Hammarstr\u00f6m S, Hamberg M, Samuelsson B, Duell EA, Stawiski M, Voorhees JJ. Increased concentrations of nonesterified arachidonic acid, 12L hydroxy 5,8,10,14 eicosatetraenoic acid, prostaglandin E2, and prostaglandin F(2\u03b1) in epidermis of psoriasis. Proc Natl Acad Sci USA. 1975;72:5130\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1630_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21:1\u201312.","journal-title":"Int J Mol Sci"},{"key":"1630_CR71","first-page":"1","volume":"6","author":"A Ruyssen-Witrand","year":"2020","unstructured":"Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. BMJ Open Sport Exerc Med. 2020;6:1\u201312.","journal-title":"BMJ Open Sport Exerc Med"},{"key":"1630_CR72","first-page":"47","volume":"19","author":"S Xu","year":"2021","unstructured":"Xu S, Gao X, Deng J, Yang J, Pan F. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis. J Dtsch Dermatol Ges. 2021;19:47\u201356.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1630_CR73","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77:890\u20137.","journal-title":"Ann Rheum Dis"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01630-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01630-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:02:35Z","timestamp":1783432955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-025-01630-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1038\/s41418-025-01630-4","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Mouse experiments were performed under the approved project of the Austrian Federal Ministry of Education, Science nd Research (BMWF): Wagner E. 171\/18. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}